All Journals > Infection Control and Hospital Epidemiology > October 2006 > Decrease in HA‐MRSA Infections and Savings From Glycopeptide Use

Article Tools

Search for Related Articles

Highlighted Article

NHSN Annual Update:
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections

Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

Antimicrobial-resistant pathogens that cause healthcare-associated infections (HAIs) pose an ongoing and increasing challenge to hospitals, both in the clinical treatment of patients and in the prevention of the cross-transmission of these problematic pathogens.  Describing the magnitude of the problem with respect to these antimicrobial-resistant pathogens is challenging, because the levels of antimicrobial resistance vary for different types of healthcare facilities and for different geographic areas, and some resistance phenotypes are difficult for laboratories to detect. However, the findings from such attempts may help the infection control and public health communities target problems and utilize resources more efficiently.

In the News

Featured in The Times
"Ireland 'losing war' on superbug" February 15, 2009
Challenges of Implementing National Guidelines for the Control and Prevention of Methicillin‐Resistant Staphylococcus aureus Colonization or Infection in Acute Care Hospitals in the Republic of Ireland
Fidelma Fitzpatrick, MD; Fiona Roche, PhD; Robert Cunney, MB; Hilary Humphreys, MD; Strategy for the Control of Antimicrobial Resistance in Ireland Infection Control Subcommittee
The research, published in Infection Control and Hospital Epidemiology, found one third of hospitals did not have a written policy on antibiotic use, and only 35% had an antibiotic stewardship programme.

October 2006

Volume 27, Number 10
Infect Control Hosp Epidemiol 2006;27:1131–1132
0899-823X/2006/2710-0020$15.00
DOI: 10.1086/507969
Concise Communication

The Decrease in Healthcare‐Associated Methicillin‐Resistant Staphylococcus aureus Infections and Savings From Glycopeptide Use

Diler Coşkun, MD;

Jale Aytaç, MD2

From the Department of Microbiology, Medical Faculty, Istanbul Science University (D.C.), and the Department of Infectious Diseases and Clinical Microbiology, Florence Nightingale Hospital (J.A.), Caglayan, Istanbul, Turkey

We evaluated changes in the rate of healthcare‐associated methicillin‐resistant Staphylococcus aureus (MRSA) infections and healthcare‐associated S. aureus infections after implementation of infection control precautions and the effect of this on glycopeptide use and expenditures for glycopeptides in a private medical center in Turkey in the years 2000‐2005. A striking decrease was obtained in the number of MRSA infections, and the expenditure for glycopeptide use also decreased.

Received March 21, 2006; accepted May 19, 2006; electronically published September 20, 2006.

Address reprint requests to Diler Coşkun, MD, Sedef cad. Ata 2‐2 Blok, D: 83, Atasehir‐Kadikoy, 34 758 Istanbul, Turkey ().

Cited by

Oguz Resat Sipahi. (2008) Economics of antibiotic resistance. Expert Review of Anti-infective Therapy 6:4, 523-539
Online publication date: 1-Sep-2008.
CrossRef
Close Popup